Elon's Vision
  • Contacts
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Editor's Pick

The HALT Fentanyl Act Doubles Down on Denialism

by
May 26, 2023
in Editor's Pick
0
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Jeffrey A. Singer

Yesterday the House of Representatives voted 289–133 to pass the HALT Fentanyl Act.* The act permanently classifies fentanyl‐​related substances (FRS)—analogs of fentanyl that differ chemically from analogs currently used medically (e.g., sufentanil, remilfentanil, alfentanil)—as Schedule 1 drugs. The Drug Enforcement Administration defines Schedule 1 drugs as having “no currently accepted medical use and a high potential for abuse.”

Set aside the fact that politicians have no way of knowing that future analogs have no potential medical use (think of all those years lost in treating mental health problems with psychedelics because the DEA determined they had no accepted medical use). Set aside the fact that keeping heroin and cannabis as Schedule 1 drugs for more than half a century has not deterred the black market from providing those drugs to consumers. What is even more mind‐​boggling is that the Trump Administration temporarily classified FRSs Schedule 1 in 2018 as an emergency measure in response to the rise in fentanyl‐​related overdose deaths, and renewed the temporary classification in 2020 through 2024. Fentanyl‐​related overdose deaths went from roughly 47,000 in 2018 to more than 81,000 in 2022. By what logic do lawmakers think that permanently extending FRSs Schedule 1 classification will somehow bring overdose deaths down?

The HALT Fentanyl Act also increases mandatory minimum sentences for people found possessing fentanyl‐​related substances. Experience shows that mandatory minimum sentences and even the death penalty do nothing to deter drug dealing and drug use. Mandatory minimums do, however, empower prosecutors to engage in coercive plea bargaining.

In testimony before the House Judiciary Committee Subcommittee on Crime and Government Surveillance last March I urged lawmakers not to go down this road.

The bill now goes to the Senate, and President Biden signals he will sign it.

The HALT Fentanyl Act is just the latest example of Congress doing the same thing over and over and expecting a different result. This is prohibition denialism.

*HALT Fentanyl Act is an acronym for “Halt All Lethal Trafficking of Fentanyl Act”

Previous Post

Representative Mooney Calls Out Fed’s CBDC Pilots

Next Post

Friday Feature: Challenger School

Next Post

Friday Feature: Challenger School

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

That Bangladesh Mask Study!

December 1, 2021

Antitrust Regulation Assumes Bureaucrats Know the “Correct” Amount of Competition

November 24, 2021
Pints of champagne could be the next ‘Brexit dividend’

Pints of champagne could be the next ‘Brexit dividend’

December 24, 2021

The Political Business Cycle 50 Years Later

0

0

0

0

The Political Business Cycle 50 Years Later

May 10, 2025

Why Elon Musk Is Right: The Case Against Subsidizing Amtrak

May 10, 2025

The Gold-Silver Ratio

May 10, 2025
Friday Feature: MCP Academy

Friday Feature: MCP Academy

May 9, 2025

Recent News

The Political Business Cycle 50 Years Later

May 10, 2025

Why Elon Musk Is Right: The Case Against Subsidizing Amtrak

May 10, 2025

The Gold-Silver Ratio

May 10, 2025
Friday Feature: MCP Academy

Friday Feature: MCP Academy

May 9, 2025

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Contacts
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.